Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/3934
Title: | Overview of nontuberculous mycobacterial disease in children | Authors: | Ford, T. J. Holland, S. M. Silcock, R. A. |
Issue Date: | 2021 | Source: | 57, (1), 2021, p. 15-18 | Pages: | 15-18 | Journal: | Journal of Paediatrics and Child Health | Abstract: | Nontuberculous mycobacteria (NTM) are ubiquitous organisms in our surrounding environment. Four distinct clinical syndromes associated with NTM infection have been described: skin and soft tissue disease, lymphadenitis, disseminated disease and pulmonary disease. In children, lymphadenitis is the most common NTM clinical entity, particularly affecting those aged 1–5 years who have no known risk factors for disease. Optimal management of NTM lymphadenitis is not entirely clear, although surgical intervention is likely a definitive therapy. Disseminated NTM disease is uncommon and only seen in the setting of immunocompromise. In previously well children, this presentation should always lead to consideration of an underlying immune defect, such as Mendelian susceptibility to mycobacterial disease. Identification of the underlying cause enables more targeted therapy and better prognostic understanding. Pulmonary NTM disease is fundamentally different to the other clinical syndromes, presenting in different hosts, who have different comorbidities, and follow a different clinical course.L20101483412021-01-13 | DOI: | 10.1111/jpc.15257 | Resources: | https://www.embase.com/search/results?subaction=viewrecord&id=L2010148341&from=exporthttp://dx.doi.org/10.1111/jpc.15257 | | Keywords: | immune deficiency;immunocompromised patient;incidence;infection sensitivity;lung disease;lymphadenitis;monogenic disorder;nonhuman;pediatrics;priority journal;prognosis;protein defect;skin disease;skin infection;soft tissue infection;syndrome;review;antimycobacterial agentautoantibody;gamma interferon receptor;immunomodulating agent;interleukin 12 receptor;atypical mycobacteriosis;atypical Mycobacterium;child;clinical feature;comorbidity;disease course;disease predisposition;disease risk assessment;genetic screening;hematopoietic stem cell transplantation;human | Type: | Article |
Appears in Sites: | Children's Health Queensland Publications |
Show full item record
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.